employees started commenting with proof.
By noon, Harrington BioSystems’ stock had fallen hard enough to trigger emergency investor calls. By late afternoon, two hospitals announced they were pausing use of the company’s devices pending review. Whistleblowers who had been ignored for years finally had people returning their calls.
I did not celebrate.continue reading …